NCT07726563Recruiting
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)
Source: ClinicalTrials.gov · Last updated 24 Jul 2026
Brief summary (registry, in English)
10-20% of patients with ALS have anti-NRIP autoantibody and the titer of anti-NRIP autoantibody is correlated with motor functional decline and mortality in ALS. The PALADIN2 clinical trial is a single arm study, which intends to enroll 20 ALS patients having anti-NRIP autoantibody in plasma. Patients will receive 3 courses of plasmapheresis per 3 months in order to maintain low concentration of anti-NRIP autoantibody in plasma. The study will follow up these patients for another 6 months after plasmapheresis. This project will potentially confirm the efficacy and safety of plasmapheresis for ALS patients having anti-NRIP autoantibody.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 19 May 2026
- Start date
- 19 May 2026
- Primary completion date
- 31 Jan 2029
- Lead sponsor
- National Taiwan University Hospital
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT07726563
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 19 May 2026 to the primary completion date, 31 Jan 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Belong to special subtype of ALS, such as primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, flail leg syndrome.
Lab values
- Blood fibrinogen level below 50 mg/dl
Other
- Under permanent ventilator support
- Cannot receive plasmapheresis treatment or serial examinations
- Under pregnancy
Who the study is looking for
- ALS patients above 20-year-old who have anti-NRIP autoantibody in plasma
- Agree to receive plasmapheresis treatment
- Agree to participate in the study and receive serial examinations
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Taiwan University Hospital Coordinator of this site? Confirm its status | Taipei City | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.